Human Genome Sciences Inc.
33
0
0
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
6 terminated/withdrawn out of 33 trials
81.3%
-5.3% vs industry average
21%
7 trials in Phase 3/4
50%
13 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
Role: collaborator
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Role: collaborator
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
Role: collaborator
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Role: collaborator
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Role: lead
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
Role: lead
Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Role: collaborator
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Role: lead
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Role: lead
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
Role: collaborator
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Role: lead
A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
Role: lead
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
Role: collaborator
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Role: lead
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Role: lead
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
Role: lead
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
Role: lead
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
Role: lead
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Role: lead
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Role: lead